IZTC NASDAQ
Invizyne Technologies Inc. Common Stock
1W: -22.3%
1M: -25.0%
3M: -1.3%
$16.50
Last traded 2025-03-10 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$157.2M
52W Range8.5-23.99
Volume12,043
Avg Volume36,900
Beta-4.51
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Heltzen
Employees29
SectorHealthcare
IndustryBiotechnology
IPO Date2024-11-13
Websiteexozymes.com
750 Royal Oaks Drive
Monrovia, NV 91016
US
Monrovia, NV 91016
US
626 415 1488
About Invizyne Technologies Inc. Common Stock
Invizyne Technologies Inc. is an American synthetic biochemical company that has developed SimplePath, an innovative platform. This technology is designed to synthesize a diverse range of chemicals, including vital substances like pharmaceuticals, fuels, and advanced materials, as well as food additives and entirely novel compounds. At its core, SimplePath is composed of specialized modules, each integrating one or more enzymes that collaboratively execute defined biocatalytic conversions. Established in 2014, Invizyne Technologies' operations are headquartered in Monrovia, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Heltzen Michael | P-Purchase | 1,767 | $10.78 | 2025-01-17 |
| Heltzen Michael | P-Purchase | 121 | $10.72 | 2025-01-16 |
| BELL LON E | 51,939 | $8.00 | 2024-11-19 | |
| Heltzen Michael | 155,818 | $3.31 | 2024-11-18 | |
| Heltzen Michael | 22,097 | $8.00 | 2024-11-18 |